Five questions for: Cara Therapeutics CEO Derek Chalmers
This article was originally published in Scrip
Executive Summary
Cara Therapeutics is one of 19 biotechnology firms to launch an initial public offering so far in 2014, so with $55.9m in IPO proceeds in the bank, president and CEO Derek Chalmers can focus on his company's late-stage development of CR845 for post-operative pain.